Azzad Asset Management Inc. ADV Grows Stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Azzad Asset Management Inc. ADV grew its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 9.8% during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 7,858 shares of the company's stock after buying an additional 699 shares during the period. Azzad Asset Management Inc. ADV's holdings in IDEXX Laboratories were worth $3,300,000 as of its most recent filing with the SEC.

Several other large investors also recently modified their holdings of IDXX. Geode Capital Management LLC boosted its stake in IDEXX Laboratories by 1.7% during the fourth quarter. Geode Capital Management LLC now owns 2,297,271 shares of the company's stock worth $948,279,000 after acquiring an additional 37,734 shares in the last quarter. Bamco Inc. NY boosted its position in shares of IDEXX Laboratories by 4.3% during the 4th quarter. Bamco Inc. NY now owns 2,005,522 shares of the company's stock worth $829,163,000 after purchasing an additional 82,264 shares in the last quarter. Invesco Ltd. grew its stake in shares of IDEXX Laboratories by 6.8% in the 4th quarter. Invesco Ltd. now owns 1,160,988 shares of the company's stock valued at $479,999,000 after buying an additional 74,324 shares during the period. Norges Bank bought a new stake in IDEXX Laboratories in the 4th quarter valued at about $412,258,000. Finally, GAMMA Investing LLC raised its stake in IDEXX Laboratories by 59,810.7% during the 1st quarter. GAMMA Investing LLC now owns 918,431 shares of the company's stock worth $3,856,950,000 after buying an additional 916,898 shares during the period. Institutional investors and hedge funds own 87.84% of the company's stock.

Analyst Ratings Changes

Several equities research analysts have recently commented on the company. Wall Street Zen downgraded IDEXX Laboratories from a "buy" rating to a "hold" rating in a report on Friday, May 30th. Leerink Partners lifted their price objective on shares of IDEXX Laboratories from $515.00 to $580.00 and gave the company an "outperform" rating in a report on Wednesday, June 11th. Morgan Stanley upped their target price on shares of IDEXX Laboratories from $548.00 to $558.00 and gave the stock an "overweight" rating in a report on Monday, May 5th. Finally, Stifel Nicolaus raised their price target on shares of IDEXX Laboratories from $460.00 to $510.00 and gave the company a "hold" rating in a research report on Monday, May 19th. Four research analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $546.00.

Insider Activity at IDEXX Laboratories

In other IDEXX Laboratories news, Director M Anne Szostak sold 1,260 shares of the business's stock in a transaction on Wednesday, May 21st. The stock was sold at an average price of $512.34, for a total value of $645,548.40. Following the transaction, the director now owns 1,801 shares of the company's stock, valued at approximately $922,724.34. The trade was a 41.16% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 0.98% of the stock is currently owned by company insiders.

IDEXX Laboratories Stock Up 1.2%

Shares of NASDAQ IDXX traded up $6.07 during trading on Monday, hitting $528.77. The stock had a trading volume of 371,831 shares, compared to its average volume of 649,497. The firm has a fifty day moving average of $476.46 and a two-hundred day moving average of $445.36. The company has a market capitalization of $42.52 billion, a PE ratio of 49.56, a PEG ratio of 3.41 and a beta of 1.55. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.31 and a quick ratio of 0.95. IDEXX Laboratories, Inc. has a 12 month low of $356.14 and a 12 month high of $540.79.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The company reported $2.96 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.93 by $0.03. IDEXX Laboratories had a net margin of 22.78% and a return on equity of 55.82%. The business had revenue of $998.43 million during the quarter, compared to the consensus estimate of $998.25 million. During the same period in the prior year, the firm posted $2.71 EPS. The firm's quarterly revenue was up 3.6% compared to the same quarter last year. As a group, equities research analysts forecast that IDEXX Laboratories, Inc. will post 11.93 EPS for the current fiscal year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.